At Critical Care Reviews, we aim to bring the latest evidence straight to clinicians without barrier or hinderance. In our opinion, there is no better way to do so than with our free livestreams, including the trial results presentation, an independent editorial, questions from viewers worldwide, and an expert panel discussion.
Unlike most conferences, we afford sufficient time to assess the robustness of the trial, fully understand the intricacies of the data, and clarify what the results mean for clinicial practice.
To complete the session, we try to coordinate with the publication of the trial manuscript, so we have a simultaneous presentation - publication.
Typically 90 minutes to 2 hours in length
The sequel to the landmark TTM trial result, published in NEJM in 2012. TTM2 is a international, multicentre, parallel group, non-commercial, randomised, superiority trial in which a target temperature of 33°C after out-of-hospital cardiac arrest will be compared to normothermia with early treatment of fever (≥37.8°C).
The ACTIV4-a, ATTACC, & REMAP-CAP investigators will present the results of this multi-platform trial, in which critically ill adults were randomized to receive therapeutic anticoagulation with heparin or pharmacological thromboprophylaxis as per local usual care.The preprint of the main paper was published on March 12th in MedRxiv.
This Brazilian 2x2 factorial trial will randomise ICU patients at moderate to high risk for death or AKI to receive a balanced crystalloid solution (Plasma-Lyte®) or 0.9% saline and to receive crystalloids by rapid bolus infusion (999 mL/h) or slow infusion (333 mL/h) whenever plasma expansion is needed.
REMAP-CAP IL-6 Receptor Antagonist Domain Results Livestream
This is the REMAP-CAP IL-6 receptor antagonist domain results presentation, recorded February 25th. The presentation was accompanied by a simultaneous publication in the New England Journal of Medicine.
Prof Derek Angus (Pittsburgh, USA) & Dr Liz Lorenzi (Berry Consultants, Austin, USA), set the scene with talks on the adaptive platform design of REMAP-CAP, and its underlying Bayesian framework, respectively. Next, Dr Lennie Derde (Utrecht, The Netherlands) presents the full results of the IL-6 receptor antagonist domain, followed by an independent editorial by Prof Tim Walsh (Edinburgh, Scotland). Lennie and her co-investigators reply to the editorial and questions from viewers. The session ends with a panel discussion, including external experts Dr David Harrison (Chief Statistician, ICNARC, London), Prof Anders Perner (Copenhagen, Denmark), and Prof Anthony Gordon (London, England), the lead investigator for the IL-6 RA domain at REMAP-CAP.
1:37 - Derek Angus - The Beauty of Adaptive Designs
19:22 - Liz Lorenzi -.The Statistical Framework of REMAP-CAP
42:50 - Lennie Derde - The Results
1:09:05 - Tim Walsh - The Editorial
1:35:40 - Lennie Derde et al - Reply to the Editorial
1:43:52 - Questions va Chris Nutt
1:54:10 - Panel Discussion